Clinical trials: Soft-tissue Sarcomas
Osteosarcoma, Sarcoma
ARTEMIS-002: HS-20093 in Patients With Relapsed or Refractory Osteosarcoma and Other Sarcomas
HS-20093 is a fully humanized IgG1 antibody-drug conjugate (ADC) which specifically binds to B7-H3, a target wildly expressed on solid tumor cells.
- Trial name
- NCT05830123
- Testing
- HS-20093
- Where
- 11 sites in China
- Volunteers
- 170 people
- Sponsor
- Hansoh BioMedical R&D Company
Advanced Solid Tumors
AMG 386 Drug-Drug Interaction Study With Paclitaxel
The purpose of this study is to evaluate the pharmacokinetics of paclitaxel when given alone and in combination with AMG 386 to determine whether AMG 386 alters the pharmacokinetics of paclitaxel
- Trial name
- NCT01992341
- Testing
- AMG 386, Paclitaxel
- Where
- 2 sites in United States
- Volunteers
- 35 people
- Sponsor
- Amgen
Renal Medullary Carcinoma (RMC), Epithelioid Sarcoma
Compassionate Use of Ubamatamab
Provide Compassionate Use of Ubamatamab
- Trial name
- NCT07502716
- Testing
- ubamatamab
- Sponsor
- Regeneron Pharmaceuticals
Advanced Solid Tumor, Advanced Cancer
NBE-002 in Patients With Advanced Solid Tumors
This first-in-human study will evaluate the recommended dose for further clinical development, safety, tolerability, anti-tumor activity, immunogenicity, pharmacokinetics and pharmacodynamics of NBE-002, a novel anti-ROR1…
- Conditions
- Advanced Solid Tumor, Advanced Cancer, Triple Negative Breast Cancer
- Trial name
- NCT04441099
- Testing
- NBE-002
- Where
- 3 sites in United States
- Volunteers
- 12 people
- Sponsor
- NBE-Therapeutics AG
Advanced Solid Tumor, Soft Tissue Sarcoma Adult
Phase 1 Study of SON-1010 in Adult Patients With Advanced Solid Tumors
This is a Phase 1, first-in-human, open-label, adaptive-design outpatient study to assess the safety, tolerability, and PK/PD of SON-1010 administered to patients with advanced solid tumors.
- Trial name
- NCT05352750
- Testing
- SON-1010
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Sonnet BioTherapeutics
Osteosarcoma
A Clinical Study of PD-L1 Antibody ZKAB001(Drug Code) in Limited Stage of High-grade Osteosarcoma
This is a Phase 1+2, open-label, dose-escalation, and multidose study, aiming to investigate the safety, tolerability and pharmacokinetics of ZKAB001 (a fully human monoclonal antibody targeting the Programmed Death - Ligand 1…
- Trial name
- NCT03676985
- Testing
- ZKAB001 5mg/kg, ZKAB001 10mg/kg, ZKAB001 15mg/kg
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Lee's Pharmaceutical Limited
Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL)
A Study to Assess Long-term Safety of Tazemetostat in Adult Participants of All Ages With Any Disease Treated With Tazemetostat in a Previous Clinical Study
This study will provide continuing availability to tazemetostat for people that have previously completed participation in a tazemetostat study, either with monotherapy (single drug treatment) or combination therapy.
- Conditions
- Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), Synovial Sarcoma, Epithelioid Sarcoma (ES)
- Trial name
- TRuST (NCT02875548)
- Testing
- Tazemetostat
- Where
- 34 sites in United States, Australia and 5 more
- Volunteers
- 58 people
- Sponsor
- Epizyme, Inc.
Ovarian Cancer, Cervical Cancer
Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors
The purpose of the trial is to determine the maximum tolerated dose and to establish the safety profile of HuMax-AXL-ADC in a mixed population of patients with specified solid tumors
- Conditions
- Ovarian Cancer, Cervical Cancer, Endometrial Cancer, Non Small Cell Lung Cancer (NSCLC)
- Trial name
- NCT02988817
- Testing
- Enapotamab vedotin (HuMax-AXL-ADC)
- Where
- 41 sites in United States, Belgium and 4 more
- Volunteers
- 306 people
- Sponsor
- Genmab
Sarcoma, Lung Cancers
An Open-label, Phase I Clinical Trial of Super1 TCR-T in NY-ESO-1-positive Patients With Advanced Solid Tumors
This study was a phase I safety and tolerability clinical trial conducted in a single-center, open-label, 3+3 design with dose escalation.
- Conditions
- Sarcoma, Lung Cancers, Melanoma
- Trial name
- NCT06942143
- Testing
- Super1 TCR-T
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Guangzhou FineImmune Biotechnology Co., LTD.
Solid Tumor
A Study to Assess the Potential Effects of a Single-Dose Administration of Trabectedin on the QT Intervals of the Electrocardiogram
The purpose of this study is to assess the potential effects of trabectedin on the QT/QTc interval duration measured by electrocardiograms (ECGs) in participants with advanced solid tumor malignancies when administered at a…
- Trial name
- NCT00786838
- Testing
- Trabectedin
- Where
- 17 sites in United States, Belgium and 5 more
- Volunteers
- 76 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Clear Cell Sarcoma
QUILT-3.031: AMG 337 in Subjects With Advanced or Metastatic Clear Cell Sarcoma
This is a phase 2 study that will assess the efficacy of AMG 337 in subjects with advanced or metastatic clear cell sarcoma that contains the EWSR1-ATF1 gene fusion.
- Trial name
- NCT03132155
- Testing
- AMG 337
- Where
- 2 sites in United States
- Volunteers
- 8 people
- Sponsor
- NantPharma, LLC
Solid Tumors With PTCH1 Loss-of-function Mutations
A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations
This study employs a 2-stage design that aims to evaluate the efficacy and safety of ENV- 101, a potent Hedgehog (Hh) pathway inhibitor, in patients with refractory advanced solid tumors characterized by loss of function (LOF)…
- Trial name
- NCT05199584
- Testing
- ENV-101 (taladegib)
- Where
- 16 sites in United States
- Volunteers
- 20 people
- Sponsor
- Endeavor Biomedicines, Inc.
Ewing Family of Tumors, Rhabdomyosarcoma
PK/PD of XM22 in Children With Ewing Family of Tumors or Rhabdomyosarcoma
This is a Phase I, open label study aimed at assessing the pharmacokinetics, pharmacodynamics, the efficacy, safety, and tolerability of a single injection of XM22 in children with Ewing family of tumors or rhabdomyosarcoma…
- Trial name
- NCT01585649
- Testing
- Lipegfilgrastim
- Where
- 18 sites in Bulgaria, Czechia and 4 more
- Volunteers
- 21 people
- Sponsor
- Merckle GmbH
Sarcoma
An Efficacy and Safety Study of Trabectedin Versus Doxorubicin-Based Chemotherapy in Participants With Translocation-Related Sarcomas (TRS)
The purpose of this study is to evaluate the efficacy and safety of trabectedin compared to standard doxorubicin in participants with advanced translocation-related sarcomas (cancer of connective tissue cells) (TRS).
- Trial name
- NCT00796120
- Testing
- Trabectedin, Doxorubicin, Ifosfamide
- Where
- 21 sites in United States, France and 3 more
- Volunteers
- 121 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Endometrial Neoplasms, Ovarian Neoplasms
A Study of Catequentinib Hydrochloride (AL3818) in Endometrial, LGSOC, STS or GBM Cancers
This phase 1b/2a study evaluates the investigational oral drug catequentinib hydrochloride (AL3818), given alone or with AL58805, temozolomide, or lomustine (CCNU), in adults with advanced or metastatic solid tumors.
- Conditions
- Endometrial Neoplasms, Ovarian Neoplasms, Soft Tissue Sarcoma (STS), Glioblastoma
- Trial name
- NCT07811297
- Testing
- AL58805, AL3818, Temozolomide (TMZ)
- Where
- United States
- Volunteers
- 138 people
- Sponsor
- Advenchen Pharmaceuticals, LLC.
Tumor
Study of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid Tumors
This is a study to assess the combination of PXD101 and 5-Fluorouracil (5-FU)in patients with advanced solid tumors. The primary goal of the study is to understand the safety, anti-tumor activity, and how the study drug behaves…
- Trial name
- NCT00413322
- Testing
- belinostat, 5-Fluorouracil (5-FU)
- Where
- 3 sites in United States
- Volunteers
- 35 people
- Sponsor
- Valerio Therapeutics
Metastatic Solid Tumor, Colorectal Cancer
Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors
This open-label, phase Ib/II study of surufatinib in combination with tislelizumab will evaluate the safety, tolerability, PK and efficacy in patients with advanced solid tumors.
- Conditions
- Metastatic Solid Tumor, Colorectal Cancer, Neuroendocrine Tumors, Small Cell Lung Cancer
- Trial name
- NCT04579757
- Testing
- Surufatinib and Tislelizumab _ Part 1, Surufatinib and Tislelizumab _ Part 2
- Where
- 18 sites in United States
- Volunteers
- 87 people
- Sponsor
- Hutchmed
Soft Tissue Sarcoma
A Japanese Trial of TH-302 in Subjects With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma
This is a Phase 2, single-arm, Japanese multicenter trial to evaluate the safety, tolerability, and efficacy of TH-302 in combination with doxorubicin in subjects with locally advanced unresectable or metastatic soft tissue…
- Trial name
- NCT02255110
- Testing
- TH-302, Doxorubicin
- Where
- 2 sites in Japan
- Volunteers
- 6 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Sarcoma, Soft Tissue
Study Evaluating the Safety and Efficacy of ABT-510 in Subjects With Locally Advanced or Metastatic Soft Tissue Sarcoma
The primary objective of this study is to assess the safety and effectiveness of ABT-510 in subjects with locally advanced or metastatic soft tissue sarcoma.
- Trial name
- NCT00061659
- Testing
- ABT-510 - Thrombospondin-1 mimetic
- Where
- 5 sites in United States
- Volunteers
- 88 people
- Sponsor
- Abbott
Breast Cancer, Colorectal Cancer
Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies
This is a phase I/II, non randomized, open-label, dose escalation study to investigate the safety, tolerability and preliminary efficacy of CB-103.
- Conditions
- Breast Cancer, Colorectal Cancer, Adenoid Cystic Carcinoma, Non-hodgkin Lymphoma
- Trial name
- NCT03422679
- Testing
- CB-103
- Where
- 17 sites in United States, France and 4 more
- Volunteers
- 79 people
- Sponsor
- Cellestia Biotech AG